Skip to main content

ILLUMINA, INC.

For the period ended Dec 28, 2025. Filed Feb 12, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 12, 2026

ILMN$214.91-2.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

7. Supplemental Balance Sheet Details

Accounts Receivable

In millionsDecember 28,2025December 29,2024
Trade accounts receivable, gross$861$744
Allowance for credit losses(7)(9)
Total accounts receivable, net$854$735

Inventory

In millionsDecember 28,2025December 29,2024
Raw materials$254$225
Work in process398404
Finished goods4531
Inventory, gross697660
Inventory reserve(133)(113)
Total inventory, net$564$547

Property and Equipment

In millionsDecember 28,2025December 29,2024
Leasehold improvements$755$772
Machinery and equipment705683
Computer hardware and software493478
Furniture and fixtures4353
Buildings4444
Construction in progress8239
Total property and equipment, gross2,1222,069
Accumulated depreciation(1,363)(1,254)
Total property and equipment, net$759$815

Accrued Liabilities

In millionsDecember 28,2025December 29,2024
Contract liabilities, current portion$270$260
Accrued compensation expenses (1)249252
Accrued taxes payable107101
Operating lease liabilities, current portion7879
Other, including warranties (2)142135
Total accrued liabilities$846$827

(1)Includes employee separation costs related to restructuring activities.

(2)See table below for changes in the reserve for product warranties.

Changes in the reserve for product warranties were as follows:

In millions
Balance as of January 1, 2023$18
Additions charged to cost of product revenue42
Repairs and replacements(39)
Balance as of December 31, 202321
Additions charged to cost of product revenue42
Repairs and replacements(45)
Balance as of December 29, 202418
Additions charged to cost of product revenue28
Repairs and replacements(29)
Balance as of December 28, 2025$17

Restructuring

In 2023, we implemented a cost reduction initiative that included workforce reductions, consolidation of certain facilities, and other actions to reduce expenses as part of a plan to realign operating expenses while maintaining focus on our innovation roadmap and sustainable long-term growth. In Q1 2025, we implemented an incremental cost reduction initiative that included optimizing stock-based compensation and non-labor spending, as well as workforce reductions, to help mitigate the expected impact of a reduction in revenue and operating income from our Greater China business and the uncertainty in the U.S. government’s funding of the National Institutes of Health.

A summary of the pre-tax restructuring charges is as follows:

In millions202520242023Cumulative charges recorded since inception
Employee separation costs$47$12$48$107
Asset impairment charges (1)—46100146
Other costs—448
Total restructuring charges (2)$47$62$152$261

(1)For 2024, relates to impairment of right-of-use assets and leasehold improvements for Foster City campus and other property in San Diego.

For 2023, primarily relates to impairment of right-of-use assets and leasehold improvements for our i3 and Foster City campuses.

(2)For 2025, $26 million was recorded in SG&A expense, $16 million in R&D expense, and remainder in cost of revenue.

For 2024, $59 million was recorded in SG&A expense, $2 million in R&D expense, and remainder in cost of revenue.

For 2023,$122 million was recorded in SG&A expense, $24 million in R&D expense, and remainder in cost of revenue.

Total restructuring charges for 2024 and 2023 primarily related to the Core Illumina segment.

In 2024, we recorded right-of-use asset impairments of $12 million and $19 million related to our campus in Foster City, California and another property in San Diego, California, respectively. In 2023, we recorded right-of-use asset impairments of $38 million and $21 million related to our i3 campus in San Diego and our campus in Foster City, respectively. The impairments were determined by comparing the fair values of the impacted right-of-use assets to the carrying values of the assets as of the impairment measurement date. The fair values of the right-of-use assets were estimated using the discounted future cash flows method, which includes estimates and assumptions for future sublease rental rates that reflect current sublease market conditions, as well as discount rates. The estimates and assumptions used in our assessments represent Level 3 measurements because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. In 2024, we recorded $14 million of leasehold improvement impairments related to our Foster City campus and, in 2023, we recorded $16 million and $22 million of leasehold improvement impairments related to our i3 and Foster City campuses, respectively. The right-of-use asset and leasehold improvement impairments were recognized in selling, general and administrative expense.

A summary of the restructuring liability is as follows:

In millionsEmployee Separation CostsOther CostsTotal
Amount recorded in accrued liabilities as of December 31, 2023$17$1$18
Expense recorded12416
Cash payments(24)(2)(26)
Adjustments to accrual(3)(1)(4)
Amount recorded in accrued liabilities as of December 29, 2024224
Expense recorded47—47
Cash payments(42)(2)(44)
Adjustments to accrual———
Amount recorded in accrued liabilities as of December 28, 2025$7$—$7

Indemnification Liability

In connection with the acquisition of GRAIL, we assumed a performance-based award for which vesting was based on GRAIL’s future revenues and had an aggregate potential value of up to $78 million. Prior to the Spin-Off of GRAIL in 2024, it was not probable that the performance conditions associated with the award would be achieved and, therefore, no share-based compensation expense was recognized in the consolidated statements of operations. In connection with the Spin-Off, this award was assumed by GRAIL. For a period of 2.5 years following the Spin-Off, we are obligated to indemnify GRAIL for cash payments that become earned and payable related to this award. The indemnification is accounted for in accordance with ASC 460. As of both December 28, 2025 and December 29, 2024, we recognized a non-contingent liability of $1 million related to this indemnification.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.